ada standards of care 2025 obesity pharmacotherapy glp-1 The American Diabetes Association Releases in Diabetes-- ada standards of care 2025

However, a growing number of patients encounter a final hurdle: loose, hanging skin

New weight-loss pill may be more accessible than injections

About three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and many more would like to

Newer weight loss drugs, including GLP-1 medications, are being studied for their effects on heart health

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Patent law is only one part of a much broader equation.The growing burden of diabetes across Africa provides an opportunity to rethink how intellectual property, public health and industrial policy interact before the continent faces another access crisis.The legal tools already exist.The more difficult question is whether governments are prepared to use them and whether the international community is willing to support a model of pharmaceutical innovation that rewards research while recognising that access to essential medicines is, ultimately, a matter of public interest.This is a co-published article, originally published on WIPR.